Table 2. Clinical and pathologic characteristics of 46 patients with allele data from RTOG trials 9708 and 9905.
| Wildtype TT | Variant TG or GG | p-value | ||
| (n = 36) | (n = 10) | |||
| Age | Median (min–max) | 61 years (36–81) | 56 years (39–68) | 0.16 |
| Race | White | 29 (81%) | 9 (90%) | 0.66 |
| Non-white | 7 (19%) | 1 (10%) | ||
| ECOG score | 0 | 28 (78%) | 8 (80%) | 1.0 |
| 1–2 | 8 (22%) | 2 (20%) | ||
| Histology | Adenocarcinoma | 31 (86%) | 9 (90%) | 0.74 |
| Adenosquamous | 3 (8%) | 1 (10%) | ||
| Other | 2 (6%) | 0 | ||
| Stage | IB/IC/IIA/IIB | 26 (72%) | 6 (60%) | 0.46 |
| IIIA/IIIC | 10 (28%) | 4 (40%) | ||
| FIGO grade | 1–2 | 19 (53%) | 6 (60%) | 0.73 |
| 3 | 17 (47%) | 4 (40%) | ||
| MMI | >50% | 31 (86%) | 8 (80%) | 0.64 |
| LVI | 19 (53%) | 5 (50%) | 0.88 |
Key: min = minimum; max = maximum; ECOG score = Eastern Cooperative Oncology Group performance status score; FIGO = International Federation of Gynecology and Obstetrics; MMI = myometrial invasion; LVI = lymphovascular invasion.